论文部分内容阅读
目的观察中医药分阶段结合化疗治疗Ⅲ、Ⅳ期肺腺癌的临床疗效。方法采用前瞻性、多中心、随机对照的临床研究方法 ,将90例患者分为治疗组(44例)和对照组(46例)。对照组只予化疗治疗;治疗组行化疗联合中医药治疗,化疗期间服用抗瘤增效方,化疗结束后服用肺岩宁方。主要观察指标为近期疗效、生存期、卡氏评分、主要临床症状、不良反应等。结果近期疗效治疗组优于对照组(P<0.05);中位生存期治疗组为16.63个月,高于对照组的11.60个月,差异有显著性(P<0.05);1年、3年、5年生存率治疗组均高于对照组(P<0.05);卡氏评分、临床症状改善情况治疗组优于对照组意义(P<0.05)。结论中医药分阶段联合化疗提高近期疗效、延长晚期肺腺癌生存期及改善生存质量均有良好效果。
Objective To observe the clinical efficacy of traditional Chinese medicine combined with chemotherapy in stages Ⅲ and Ⅳ of lung adenocarcinoma. Methods Ninety patients were divided into treatment group (44 cases) and control group (46 cases) by prospective, multicenter and randomized controlled clinical study. The control group only chemotherapy; the treatment group chemotherapy combined with traditional Chinese medicine, chemotherapy, taking anti-tumor side effect, chemotherapy after taking lung Yanning side. The main indicators for the short-term efficacy, survival, Karnofsky score, the main clinical symptoms, adverse reactions. Results The efficacy of the treatment group was better than that of the control group (P <0.05). The median survival time of the treatment group was 16.63 months, which was 11.60 months higher than that of the control group (P <0.05) , 5-year survival rate of the treatment group were higher than the control group (P <0.05); Karnofsky score, the clinical symptoms of the treatment group was better than the control group (P <0.05). Conclusion Traditional Chinese medicine combined with chemotherapy in stages to improve the short-term efficacy, prolong the survival of advanced lung adenocarcinoma and improve the quality of life have good results.